The name versus the record: every claimed effect at its true grade

Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.

Compounded, not FDA-approved

DSIP (emideltide) is not FDA approved and no human efficacy has been established. In July 2026 FDA proposed not to allow it for pharmacy compounding.

RESEARCH-ONLY in the United States. No FDA-approved product contains emideltide; Drugs@FDA queries for emideltide and for delta sleep-inducing peptide return no matches. FDA lists Emideltide (DSIP) on its page of bulk drug substances that may present significant safety risks in compounding, and at the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting FDA proposed that emideltide (free base) and emideltide acetate NOT be included on the 503A Bulks List. Trade press reported the committee also voted against it, the only one of the seven peptides reviewed to be rejected; that vote is press-reported, non-binding, and the rulemaking is pending.

The name versus the record: every claimed effect at its true grade
Claimed effect	Best available study and its result	Evidence grade	Source
Induces or maintains sleep in chronic insomnia	Bes 1992, the only double-blind parallel-group placebo-controlled trial (n=16): weak effects, partly attributable to placebo-group drift; authors conclude DSIP is not likely to be of major therapeutic benefit	Human RCT	source
Improves sleep versus placebo in crossover testing	Monti 1987, randomized double-blind crossover (n=6): no significant differences versus baseline or placebo; improvement of little clinical significance	Human RCT	source
Normalizes sleep with repeated dosing	Schneider-Helmert 1987 (n=14): large reported gains, but no placebo arm; comparison was to external healthy controls, a design FDA says cannot carry an effectiveness conclusion	Human trial	source
Produces lasting normalization for months	Kaeser 1984, open uncontrolled series (n=7): 6 of 7 reported normalized 3 to 7 months; no control, no blinding	Human trial	source
Increases EEG delta power in humans	Pomfrett 2009, randomized, the most recent human study (n=24): delta rhythm paradoxically and significantly REDUCED during anaesthesia; heart rate up, anaesthetic depth lightened	Human RCT	source
Relieves opioid and alcohol withdrawal	Dick 1984, open uncontrolled series (n=107): authors claim improvement in 97 and 87 percent but concede no conclusion is possible on maintenance; serious adverse events included progressive hypotension. FDA: insufficient evidence	Human trial	source
Improves narcolepsy	Schneider-Helmert 1984: a single one-patient case report; the entire literature for this indication	human-observational	source
Is an endogenous human sleep hormone	Kovalzon and Strekalova 2006 review: gene, precursor protein and receptor never isolated; sleep-factor hypothesis extremely poorly documented and still weak	Review or guideline	source
Is safe for ongoing use	No dedicated human safety study, no toxicology program, no long-term data at any dose; FDA lacks sufficient information to know whether it would cause harm	Absence of evidence	source

Each row takes an effect implied by the name or repeated by vendors, and puts it next to the best study that exists for it, that study's actual result, and its evidence grade.

Best available means the strongest design that addressed the claim, not the most favorable result. Where the strongest design found nothing, that is the row. This table is the site's thesis in miniature: the name promises delta sleep, and the record, at its best grade, does not deliver it.